313 related articles for article (PubMed ID: 25528311)
1. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial.
Lafeber M; Grobbee DE; Schrover IM; Thom S; Webster R; Rodgers A; Visseren FL; Bots ML; Spiering W
Int J Cardiol; 2015 Feb; 181():193-9. PubMed ID: 25528311
[TBL] [Abstract][Full Text] [Related]
2. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
4. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
5. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
[TBL] [Abstract][Full Text] [Related]
6. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
7. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
[TBL] [Abstract][Full Text] [Related]
8. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A;
JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278
[TBL] [Abstract][Full Text] [Related]
9. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
12. Randomized Polypill crossover trial in people aged 50 and over.
Wald DS; Morris JK; Wald NJ
PLoS One; 2012; 7(7):e41297. PubMed ID: 22815989
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
[TBL] [Abstract][Full Text] [Related]
14. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Muñoz D; Uzoije P; Reynolds C; Miller R; Walkley D; Pappalardo S; Tousey P; Munro H; Gonzales H; Song W; White C; Blot WJ; Wang TJ
N Engl J Med; 2019 Sep; 381(12):1114-1123. PubMed ID: 31532959
[TBL] [Abstract][Full Text] [Related]
15. A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison Company) compared to simvastatin (Zocor) in hypercholesterolemic subjects.
Assawawitoontip S; Wiwanitkit V
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S118-24. PubMed ID: 12188401
[TBL] [Abstract][Full Text] [Related]
16. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
17. Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure.
Poulter NR; Savopoulos C; Anjum A; Apostolopoulou M; Chapman N; Cross M; Falaschetti E; Fotiadis S; James RM; Kanellos I; Szigeti M; Thom S; Sever P; Thompson D; Hatzitolios AI
Hypertension; 2018 Oct; 72(4):870-873. PubMed ID: 30354703
[TBL] [Abstract][Full Text] [Related]
18. ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk.
Sergienko IV; Ansheles AA; Drapkina ОМ; Gornyakova NB; Zubareva MY; Shepel RN; Kuharchuk VV; Boytsov SA
Ter Arkh; 2019 May; 91(4):90-98. PubMed ID: 31094482
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.
Kim SH; Kim MK; Seo HS; Hyun MS; Han KR; Cho SW; Kim YK; Hoon Park S
Clin Ther; 2013 Sep; 35(9):1350-60.e1. PubMed ID: 23998970
[TBL] [Abstract][Full Text] [Related]
20. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
Trials; 2011 Jan; 12():3. PubMed ID: 21205325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
